Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

What Is the Cost of Disease Progression Among Patients with Indolent or Aggressive Non-Hodgkin Lymphoma (NHL)?

Nicole Engel-Nitz, PhD, Stacey Dacosta Byfield, PhD MPH, Timothy Bancroft, PhD, Anderson J. Amy, M.S., Carolina Reyes, PhD, May Chen, MD, Matthew J. Matasar, MD MS

Blood (2016) 128 (22): 5957.

https://doi.org/10.1182/blood.V128.22.5957.5957

Published: 2016

Journal Articles

Real-World Health Care Utilization and Costs Among Patients Newly Initiating Systemic Therapy for Chronic Lymphocytic Leukemia (CLL) in the United States

Matthew J. Matasar, MD MS, Stacey Dacosta Byfield, PhD MPH, Cori Blauer-Peterson, MPH, Melissa Montez, PharmD, Carolina Reyes, PhD, Anthony Masaquel, PhD MPH

Blood (2016) 128 (22): 5928.

https://doi.org/10.1182/blood.V128.22.5928.5928

Published: 2016

Journal Articles

What Do Patients Prioritize in Selecting Chronic Lymphocytic Leukemia (CLL) Treatments?

Carol Mansfield, PhD, Anthony Masaquel, MPH, PhD, Jessie Sutphin, Elisa S Weiss, PhD, Meghan E. Gutierrez, Jennifer Wilson, Jia Li, PhD, Carolina Reyes, PhD

Blood (2016) 128 (22): 1239.

https://doi.org/10.1182/blood.V128.22.1239.1239

Published: 2016

Journal Articles

What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?

Gregory F. Guzauskas, MSPH, PhD, Anthony Masaquel, MPH, PhD, Carolina Reyes, PhD, Kenneth Wilhelm, MD, Tania Krivasi, MSc, David L. Veenstra, PharmD, PhD

Blood (2016) 128 (22): 3605.

https://doi.org/10.1182/blood.V128.22.3605.3605

Published: 2016

Journal Articles

Differences in Patients with Progressive Versus Non-Progressive AML, CLL, or NHL: Implications for Proposed Bundled Payment Strategies

Stacey Dacosta Byfield, PhD MPH, Nicole Engel-Nitz, PhD, Timothy Bancroft, PhD, Amy J Anderson, MS, Carolina Reyes, PhD, Arliene Ravelo, MPH, Sarika Ogale, PhD, May Chen, MD, Matthew J. Matasar, MD MS

Blood (2015) 126 (23): 4528.

https://doi.org/10.1182/blood.V126.23.4528.4528

Published: 2015

Journal Articles

Real-World Outcomes Among Elderly Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Bruno C Medeiros, MD, Sacha Satram-Hoang, PhD, Khang Q. Hoang, DO, Faiyaz Momin, MS, Deborah Hurst, MD, Carolina Reyes, PhD

Blood (2014) 124 (21): 2271.

https://doi.org/10.1182/blood.V124.21.2271.2271

Published: 2014

Journal Articles

Comparative Effectiveness of Chemotherapy in an Elderly Acute Myeloid Leukemia Population in the United States

Bruno C Medeiros, MD, Sacha Satram-Hoang, PhD, Khang Q. Hoang, DO, Faiyaz Momin, MS, Deborah Hurst, MD, Carolina Reyes, PhD

Blood (2014) 124 (21): 2272.

https://doi.org/10.1182/blood.V124.21.2272.2272

Published: 2014

Journal Articles

Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Carolina Reyes, PhD, Gregory Gazauskas, PhD, Ursula Becker, MSc, Santiago Moreno, David L. Veenstra, PharmD, PhD

Blood (2014) 124 (21): 1324.

https://doi.org/10.1182/blood.V124.21.1324.1324

Published: 2014

Journal Articles

Big Data Analysis of Treatment Patterns and Outcomes Among Elderly Medicare Acute Myeloid Leukemia Patients

Sacha Satram-Hoang, PhD, Carolina Reyes, PhD, Khang Q. Hoang, DO, Faiyaz Momin, MS, Deborah Hurst, MD, Bruno C Medeiros, MD

Blood (2014) 124 (21): 3698.

https://doi.org/10.1182/blood.V124.21.3698.3698

Published: 2014

Journal Articles

Differences In Treatment Patterns and Costs Among Diffuse Large B-Cell Lymphoma Patients Treated In The Clinic Vs. The Hospital Outpatient Setting

Carolina Reyes, PhD, Stacey Dacosta Byfield, Laura K. Becker, MS, Art Small, MD

Blood (2013) 122 (21): 1751.

https://doi.org/10.1182/blood.V122.21.1751.1751

Published: 2013

Journal Articles

How Many Life Years Have Been Saved In The United States From Using Rituximab Plus Chemotherapy Compared To Chemotherapy Alone From 1998-2013

Mark Danese, PhD, Michelle Gleeson, PhD, Marc Halperin, Sandra Skettino, M.D., Carolina Reyes, PhD

Blood (2013) 122 (21): 2937.

https://doi.org/10.1182/blood.V122.21.2937.2937

Published: 2013

Journal Articles

Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma,

Xiaolei Zhou, Jianmin Wang, Jessica Zhang, Catherine Copley-Merriman, Yasuhiro Torigoe, Carolina Reyes, PhD, John F. Seymour, MD, PhD, Armando Lopez-Guillermo, MD, Fritz C. Offner, MD, PhD, Marek Trneny, Gilles Andre Salles

Blood (2011) 118 (21): 3661.

https://doi.org/10.1182/blood.V118.21.3661.3661

Published: 2011

Journal Articles

Is There a Difference in Treatment Patterns Among Follicular Lymphoma Patients Receiving Care in the Outpatient Hospital Versus the Community Clinic Setting?

Sacha Satram-Hoang, Ph.D., Carolina Reyes, PhD

Blood (2011) 118 (21): 3134.

https://doi.org/10.1182/blood.V118.21.3134.3134

Published: 2011

Journal Articles

Economic Impact of Disease Progression In Follicular Non-Hodgkin's Lymphoma.

Sacha-Satram Hoang, PhD, Stephen Gruschkus, PhD, Joseph Darragh, MS, Michael Forsyth, RPh, MBA, Roy Beveridge, MD, Carolina Reyes, PhD

Blood (2010) 116 (21): 1522.

https://doi.org/10.1182/blood.V116.21.1522.1522

Published: 2010

Journal Articles

Symptom Burden in Patients with Follicular Lymphoma Undergoing Maintenance Treatment with Rituxan Compared with Observation.

Mark Walker, PhD, Edward Stepanski, PhD, Carolina Reyes, PhD, Murad Hasan, MD, DrPH, Lee S. Schwartzberg, MD

Blood (2009) 114 (22): 2498.

https://doi.org/10.1182/blood.V114.22.2498.2498

Published: 2009

Journal Articles

Patterns and Outcomes of Infused Therapy for Chronic Lymphocytic Leukemia (CLL) in a Medicare Population.

Robert Griffiths, ScD, Carolina Reyes, PhD, Michelle Gleeson, PhD, Kevin Knopf, MD, Mark Danese, PhD

Blood (2009) 114 (22): 4409.

https://doi.org/10.1182/blood.V114.22.4409.4409

Published: 2009

Journal Articles

Impact of Disease Progression On Healthcare Cost and Resource Utilization Among Follicular NHL Patients Treated within the US Oncology Network.

Stephen K Gruschkus, PhD, Joseph M Darragh, MA, Michael A Kolodziej, MD, Roy A Beveridge, MD, Michael Forsyth, RPh, MBA, Carolina Reyes, PhD

Blood (2009) 114 (22): 4543.

https://doi.org/10.1182/blood.V114.22.4543.4543

Published: 2009

Journal Articles

Cost-Effectiveness of Rituximab Post CVP Induction for the Treatment of Low-Grade NHL.

John C. Hornberger, MD, MS, Carolina Reyes, PhD, Ashwini Shewade, MS, David Loecke, PhD, Nancy Valente, MD

Blood (2007) 110 (11): 4486.

https://doi.org/10.1182/blood.V110.11.4486.4486

Published: 2007

NARROW

What Is the Cost of Disease Progression Among Patients with Indolent or Aggressive Non-Hodgkin Lymphoma (NHL)?

Real-World Health Care Utilization and Costs Among Patients Newly Initiating Systemic Therapy for Chronic Lymphocytic Leukemia (CLL) in the United States

What Do Patients Prioritize in Selecting Chronic Lymphocytic Leukemia (CLL) Treatments?

What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?

Differences in Patients with Progressive Versus Non-Progressive AML, CLL, or NHL: Implications for Proposed Bundled Payment Strategies

Real-World Outcomes Among Elderly Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Comparative Effectiveness of Chemotherapy in an Elderly Acute Myeloid Leukemia Population in the United States

Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Big Data Analysis of Treatment Patterns and Outcomes Among Elderly Medicare Acute Myeloid Leukemia Patients

Differences In Treatment Patterns and Costs Among Diffuse Large B-Cell Lymphoma Patients Treated In The Clinic Vs. The Hospital Outpatient Setting

How Many Life Years Have Been Saved In The United States From Using Rituximab Plus Chemotherapy Compared To Chemotherapy Alone From 1998-2013

Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma,

Is There a Difference in Treatment Patterns Among Follicular Lymphoma Patients Receiving Care in the Outpatient Hospital Versus the Community Clinic Setting?

Economic Impact of Disease Progression In Follicular Non-Hodgkin's Lymphoma.

Symptom Burden in Patients with Follicular Lymphoma Undergoing Maintenance Treatment with Rituxan Compared with Observation.

Patterns and Outcomes of Infused Therapy for Chronic Lymphocytic Leukemia (CLL) in a Medicare Population.

Impact of Disease Progression On Healthcare Cost and Resource Utilization Among Follicular NHL Patients Treated within the US Oncology Network.

Cost-Effectiveness of Rituximab Post CVP Induction for the Treatment of Low-Grade NHL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only